MASTER-2

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

What's the purpose of the trial?

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment.

Trial status

Accepting patients

Phase

Phase 2

Enrollment

300

Last Updated

Participating Centers

There are 10 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Lenalidomide
Bortezomib
Daratumumab
Dexamethasone
Melphalan
Teclistamab

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Arm M: Daratumumab + Lenalidomide + Bortezomib + Dexamethasone

Accepting patients

Arm C: Teclistamab + Daratumumab (MRD + Patients)

Accepting patients

Arm D: Daratumumab + Lenalidomide (MRD + Patients)

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.